Research Analysts Set Expectations for WST Q4 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) – Equities research analysts at Zacks Research raised their Q4 2025 earnings per share (EPS) estimates for West Pharmaceutical Services in a research report issued to clients and investors on Wednesday, April 9th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will earn $1.86 per share for the quarter, up from their prior estimate of $1.85. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share.

Several other equities research analysts have also recently weighed in on WST. Citigroup initiated coverage on West Pharmaceutical Services in a research note on Wednesday, January 8th. They issued a “buy” rating and a $400.00 price target on the stock. StockNews.com downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday, February 27th. Evercore ISI initiated coverage on West Pharmaceutical Services in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $275.00 price target on the stock. KeyCorp dropped their target price on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, Deutsche Bank Aktiengesellschaft raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price target for the company in a research report on Friday, February 14th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Moderate Buy” and an average price target of $332.50.

West Pharmaceutical Services Trading Down 0.1 %

NYSE:WST opened at $212.39 on Monday. The company has a current ratio of 2.79, a quick ratio of 2.23 and a debt-to-equity ratio of 0.08. West Pharmaceutical Services has a 12 month low of $187.43 and a 12 month high of $394.42. The company has a 50-day moving average price of $226.99 and a 200-day moving average price of $288.51. The stock has a market cap of $15.35 billion, a price-to-earnings ratio of 31.75, a P/E/G ratio of 6.74 and a beta of 1.22.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share for the quarter, topping analysts’ consensus estimates of $1.75 by $0.07. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. The company had revenue of $748.80 million during the quarter, compared to analyst estimates of $739.59 million.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 7th. Investors of record on Wednesday, April 30th will be issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.40%. The ex-dividend date is Wednesday, April 30th. West Pharmaceutical Services’s dividend payout ratio is currently 12.56%.

Hedge Funds Weigh In On West Pharmaceutical Services

Several hedge funds and other institutional investors have recently modified their holdings of WST. Net Worth Advisory Group boosted its position in West Pharmaceutical Services by 54.3% in the first quarter. Net Worth Advisory Group now owns 2,852 shares of the medical instruments supplier’s stock worth $639,000 after purchasing an additional 1,004 shares during the last quarter. Fifth Third Bancorp boosted its stake in shares of West Pharmaceutical Services by 13.8% during the 1st quarter. Fifth Third Bancorp now owns 12,463 shares of the medical instruments supplier’s stock worth $2,790,000 after acquiring an additional 1,511 shares during the last quarter. CX Institutional bought a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at $225,000. Assenagon Asset Management S.A. raised its holdings in West Pharmaceutical Services by 136.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 234,807 shares of the medical instruments supplier’s stock worth $52,569,000 after purchasing an additional 135,584 shares during the period. Finally, Terra Alpha Investments LLC lifted its position in West Pharmaceutical Services by 29.7% during the first quarter. Terra Alpha Investments LLC now owns 7,057 shares of the medical instruments supplier’s stock valued at $1,580,000 after purchasing an additional 1,617 shares in the last quarter. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.